-

Boundless Bio to Present at the 2022 Jefferies Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that Chief Executive Officer, Zachary Hornby, will present at the 2022 Jefferies Healthcare Conference, which will take place in New York City. Presentation details are as follows:

Date: Thursday, June 9, 2022
Time: 10:30 AM ET
Location: New York Marriott Marquis

About Boundless Bio

Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

Contacts

James Lee
Director of Business Development
Boundless Bio
jlee@boundlessbio.com

Industry:

Boundless Bio

Release Versions
English

Contacts

James Lee
Director of Business Development
Boundless Bio
jlee@boundlessbio.com

More News From Boundless Bio

Boundless Bio to Present at the 2023 Jefferies Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancers, today announced that Chief Medical Officer, Klaus Wagner, M.D., Ph.D., will present at the 2023 Jefferies Healthcare Conference which will take place in New York City. Presentation details are as follows: Date: Thursday, June 8, 2023 Time: 4:00 – 4:25 PM ET Location:...

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-355 in Patients with Solid Tumors Harboring Oncogene Amplification

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancer, today announced that the first patient has been dosed with BBI-355 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic solid tumors with oncogene amplifications (NCT05827614). ecDNA is a key driver of high copy number amplific...

Boundless Bio Presents Data on the Novel Discovery of CHK1 as an Extrachromosomal DNA (ecDNA) Essential Target in Oncogene Amplified Cancers at the American Association for Cancer Research Annual Meeting 2023

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a clinical stage next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today will present at the American Association for Cancer Research (AACR) Annual Meeting 2023, held in Orlando and virtually from April 14-19, 2023. The poster “Tumors driven by oncogene amplified extrachromosomal DNA (ecDNA) demonstrate enhanced sensitivity to cell cycle checkpoint...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.